Get the latest news, insights, and market updates on GSK (GSK plc). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Is It Time To Reassess GSK (LSE:GSK) After Its Strong Multi‑Year Share Price Run?
If you are wondering whether GSK is still attractively priced after its recent run, you are not alone and this article is for you. The share price closed at £20.38, with returns of a 7.4% decline over 7 days and a 2.0% decline over 30 days, set against gains of 11.3% year to date, 38.3% over 1 year, 64.2% over 3 years and 98.0% over 5 years. Recent headlines around GSK have focused on its position as a large pharmaceutical and biotech player, as well as ongoing interest in its product... Mar 7, 2026 - $GSK
GSK RAPT Acquisition Adds Food Allergy Asset To Immunology Growth Story
GSK (LSE:GSK) has completed its acquisition of RAPT Therapeutics, securing global rights to key immunology assets. The deal brings ozureprubart, a monoclonal antibody for severe food allergies, into GSK’s late stage pipeline outside certain Asian territories. The transaction is aimed at expanding GSK’s specialty medicine and immunology portfolio and addressing a significant unmet medical need. GSK enters this transaction with its shares at £20.38 and a 38.3% return over the past year,... Mar 7, 2026 - $GSK
7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
Opportunities in the asthma market include the growth driven by innovative therapies like dexpramipexole and depemokimab, expanding patient pools due to rising asthma prevalence, and increased awareness and diagnosis rates. Biologics and targeted therapies are reshaping treatment, presenting significant growth prospects in the evolving landscape.Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Asthma - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets. Mar 3, 2026 - $GSK
Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best cancer stocks to invest in now. On February 23, Summit Therapeutics Inc. (NASDAQ:SMMT) reiterated it is progressing with the development of ivonescimab in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). It’s undertaking multiregional Phase III clinical trials. In addition, the company has engaged GORTEC, […] Mar 2, 2026 - $GSK
GSK (LSE:GSK) Valuation Check After Strong Recent Share Price Momentum
Why GSK is on investors’ radar today With no single headline event setting the tone, GSK (LSE:GSK) is drawing attention for its recent share performance and fundamentals, prompting investors to reassess how its current valuation lines up with its financial profile. See our latest analysis for GSK. Short term, GSK’s share price return has been firm, with a 1 day move of 1.57% and a 30 day share price return of 17.29%. The 1 year total shareholder return of 54.81% and 5 year total... Mar 2, 2026 - $GSK
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple